Impact of Shexiang Baoxin Pill (MUSKARDIA) on Cardiovascular Outcomes by Baseline Hemoglobin Levels in 2,494 Patients with Chronic Stable Coronary Artery Disease: A Secondary Subgroup Analysis.

Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial.

BACKGROUND AND AIMS In SELECT, subcutaneous semaglutide (target dose 2.4 mg) weekly in adults with pre-existing cardiovascular disease and body mass index ≥27 kg/m2 without diabetes significantly reduced major adverse cardiovascular events (MACE) by 20% vs placebo. This analysis explored potential mediators of this car...

Effects of Wuqinxi on blood pressure and lipids in hypertensive middle-aged and elderly adults: a meta-analysis

Purpose This study aimed to quantify the therapeutic effects of standardized Wuqinxi exercise on blood pressure, lipid profile, and resting heart rate in middle-aged and older adults with primary hypertension, and to grade the evidence certainty using the GRADE framework. Methods We systematically searched Web of Scien...

Dapagliflozin for attenuating early anthracycline-associated cardiac changes (DAPA-AIC): a randomized, double-blind, placebo-controlled trial.

AIMS To evaluate whether dapagliflozin attenuates early cardiac functional and biomarker changes during anthracycline-based chemotherapy. MATERIALS & METHODS In this randomized, double-blind, placebo-controlled phase II trial, 94 adults were assigned 1:1 to dapagliflozin 10 mg once daily or placebo for 4 months; 90 c...

Effects of Empagliflozin on Cardiovascular Outcomes Are Consistent Across Sociodemographic Subgroups: A Real-World Analysis From the EMPRISE Study.

OBJECTIVE We aimed to explore the heterogeneity of empagliflozin treatment effects on major adverse cardiovascular events (MACE), hospitalization for heart failure (HHF), and all-cause mortality (ACM) across sociodemographic and cardiovascular disease (CVD) subgroups of adults with type 2 diabetes (T2D). RESEARCH DES...

Human epididymis protein 4 is a predictor of long-term mortality and major adverse cardiovascular events in patients with coronary artery disease

Comment on Ostrominski et al. Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations

We read with interest the report by Ostrominski et al. (1), which used two target-trial emulations to compare tirzepatide with dulaglutide or semaglutide among patients with type 2 diabetes and established atherosclerotic cardiovascular disease. The study is timely and carefully constructed. Our concern is not whether...